19th Ave New York, NY 95822, USA
Join Now

Gene Expression and Cancer Group

Portfolio Item Gene Expression and Cancer Group
BIOMEDICAL RESEARCH

We study primary brain tumors and brain metastasis; some of the most aggressive of all cancers. Both glioblastoma and brain metastasis are dismal diseases with limited therapeutic options. Advancing progress in this field towards improving outcomes for these patients is therefore critical.

Our group is designing tools to monitor and characterize brain tumors. We discovered that we could characterize brain tumors by analyzing immune cells and cell free circulating tumor DNA in cerebrospinal fluid. While no biomarker derived from liquid biopsy against these tumors has yet been integrated into clinical practice, mounting evidence reported in the literature, including our findings, point to its efficacy in the real-time evaluation of malignant disease and potential to better inform and guide the therapeutic management of patients.

Reflective of our work in the field, we were invited to participate in the writing of two Review articles (including clinical practice recommendations) on the clinical applications of liquid biopsies in brain cancer (Soffietti et al. 2022; Pascual et al. 2022) and write a News & Views article in Nature Reviews Clinical Oncology (Seoane and Escudero 2022).

We are committed to advancing research to develop novel therapeutic compounds to treat brain cancer. In 2022, we reported the preclinical development of two novel compounds that are now in clinical development:

1- Using patient-derived models, we demonstrated the efficacy and mechanism of action of a novel brain permeable BRAF inhibitor in the context of BRAF mutant melanomas that relapsed to standard of care (Bonfill-Teixidor et al. 2022). A clinical trial to test the compound is now recruiting patients in our Hospital (ISRCTN13713551).

2- Also using patient-derived models, we studied the mechanisms of action of a novel therapeutic bispecific antibody (EGFRvIII TCB) that binds both CD3 T cells and the somatic mutation EGFRvIII expressed in 20-30% of glioblastoma. The results were published (Iurlaro et al. 2022), and the graphical abstract (see Figure) featured on the front cover of the journal. This work was the basis of a clinical trial now running in VHIO (NCT05187624).

The role of the tumor microenvironment which, in the case of brain cancers, assumes a crucial role in cancer progression. Advancing insights into the tumor microenvironment promises powerful weaponry in combating cancer, regardless of heterogeneity. In this sense, we wrote an article about the advances and limitations of a new anti-cancer agent that targets TGF-β and PD-L1 (Gulley et al. 2022).

We have also reported that the cytokine LIF assumes an essential role in the tumor microenvironment and is consequently a promising therapeutic target. We have described the mechanism of action of our novel agent MSC-1 (now AZD0171) (Hallett et al. 2022). MSC-1 is a LIF neutralizing antibody developed by VHIO spin-off, Mosaic Biomedicals, founded by Joan Seoane in 2012. Mosaic Biomedicals was acquired by Medimmune/Astrazeneca in 2020. In 2022, we published the results of the phase I clinical trial (Borazanci et al. 2022, NCT03490669). A phase II clinical trial (NCT04999969) to test MSC-1 initiated patient recruitment in 2021.

VHIO Joan Seoane
Joan Seoane
Group Leader
Biosketch

Research Lines

  • Identify new therapeutic targets against brain tumors and novel biomarkers to more precisely predict response to therapy.
  • Study intratumor heterogeneity.
  • Investigate the tumor microenvironment.
  • Develop methods for non-invasive molecular diagnosis through the study of circulating biomarkers.
  • Generate patient-derived mouse models of brain cancers.

Figure: Liquid biopsies in the most common brain tumor in children.

Team

Group Leader
Joan Seoane
Staff Scientist
Ignasi Barba
Post-Doctoral Fellows
Ester Bonfill-Teixidor
Raffaella Iurlaro
Nicolás Peláez llaneza
Clara Durán
Laia Cuesta Casanova
Graduate Students
Cayetano Jesús Galera Martínez
Laura Carrillo
María López
Bioinformatician
Almudena Neva
Technicians
Isabel Cuartas
Maria Duarte
Iris Marcote
Lab Manager
Alexandra Arias

Publications

Most relevant scientific publications

  • Cufer T, Kosty MP; Curriculum Development Subgroup—ESMO/ASCO Global Curriculum Working Group. ESMO/ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2023. ESMO Open. 2023 Dec;8(6):101631.
  • E. Le Rhun, M. Weller, M. van den Bent, D. Brandsma, J. Furtner, R. Rudà, D. Schadendorf, J. Seoane, J.-C. Tonn, P. Wesseling, W. Wick, G. Minniti, S. Peters, G. Curigliano & M. Preusser, on behalf of the EANO Guidelines Committee and ESMO Guidelines Committee. Leptomeningeal metastasis from solid tumours: EANO-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. ESMO Open. 2023; 8(5):101624.
  • Seoane J. Patient-derived preclinical models to develop immunotherapies. Mol Oncol. 2023 Jul;17(7):1169-1172.
  • Hallett RM, Bonfill-Teixidor E, Iurlaro R, Arias A, Raman S, Bayliss P, Egorova O, Neva-Alejo A, McGray AR, Lau E, Bosch A, Beilschmidt M, Maetzel D, Fransson J, Huber-Ruano I, Anido J, Julien JP, Giblin P, Seoane J. Therapeutic Targeting of LIF Overcomes Macrophage-mediated Immunosuppression of the Local Tumor Microenvironment. Clin Cancer Res. 2023 Feb 16;29(4):791-804.
  • Hallett R, Bonfill-Teixidor E, Iurlaro R, Arias A, Raman S, Bayliss PE, Egorova O, Neva-Alejo A, McGray AR, Lau E, Bosch A, Beilschmidt M, Maetzel D, Fransson J, Huber-Ruano I, Anido J, Julien JP, Giblin PA, Seoane J. Therapeutic targeting of LIF overcomes macrophage mediated immunosuppression of the local tumor microenvironment. Clin Cancer Res. Epub 2022 Nov 28:CCR-21-1888.
  • Iurlaro R, Waldhauer I, Planas-Rigol E, Bonfill-Teixidor E, Arias A, Nicolini V, Freimoser-Grundschober A, Cuartas I, Martínez-Moreno A, Martínez-Ricarte F, Cordero E, Cicuendez M, Casalino S, Guardia-Reyes X, Fahrni L, Pöschinger T, Steinhart V, Richard M, Briner S, Mueller J, Osl F, Sam J, Colombetti S, Bacac M, Klein C, Pineda E, Reyes-Figueroa L, Di Somma A, González J, Nuciforo P, Carles J, Vieito M, Tabernero J, Umaña P, Seoane J. A Novel EGFRvIII T-Cell Bispecific Antibody for the Treatment of Glioblastoma. Mol Cancer Ther. 2022 Oct 7;21(10):1499-1509.
  • Bonfill-Teixidor E, Iurlaro R, Handl C, Wichmann J, Arias A, Cuartas I, Emmenegger J, Romagnani A, Mangano L, Lorber T, Berrera M, Godfried Sie C, Köchl F, Eckmann J, Feddersen R, Kornacker M, Schnetzler G, Cicuendez M, Cordero E, Topczewski TE, Ferres-Pijoan A, González J, Martínez-Ricarte F, Muñoz-Couselo E, Tabernero J, Bischoff JR, Pettazzoni P, Seoane J. Activity and Resistance of a Brain-Permeable Paradox Breaker BRAF Inhibitor in Melanoma Brain Metastasis. Cancer Res. 2022 Jul 18;82(14):2552-2564.
  • Borazanci E, Schram AM, Garralda E, Brana I, Vieito Villar M, Spreafico A, Oliva M, Lakhani NJ, Hoffman K, Hallett RM, Maetzel D, Hua F, Hilbert J, Giblin P, Anido J, Kelly A, Vickers PJ, Wasserman R, Seoane J, Siu LL, Hyman DM, Hoff DV, Tabernero J. Phase I, first-in-human study of MSC-1 (AZD0171), a humanized anti-leukemia inhibitory factor monoclonal antibody, for advanced solid tumors. ESMO Open. 2022 Aug;7(4):100530.
  • Rubio-Perez C, Planas-Rigol E, Trincado JL, Bonfill-Teixidor E, Arias A, Marchese D, Moutinho C, Serna G, Pedrosa L, Iurlaro R, Martínez-Ricarte F, Escudero L, Cordero E, Cicuendez M, Ruiz S, Parra G, Nuciforo P, Gonzalez J, Pineda E, Sahuquillo J, Tabernero J, Heyn H*, Seoane J*. Immune cell profiling of the cerebrospinal fluid enables the characterization of the brain metastasis microenvironment. Nature Communications. 2021
  • Escudero L, Llort A, Arias A, Diaz-Navarro A, Martínez-Ricarte F, Rubio-Perez C, Mayor R, Caratú G, Martínez-Sáez E, Vázquez-Méndez É, Lesende-Rodríguez I, Hladun R, Gros L, Ramón y Cajal S, Poca M, Puente X, Sahuquillo J, Gallego S, Seoane J. Circulating tumour DNA from the cerebrospinal fluid allows the characterisation and monitoring of medulloblastoma. Nature Communications. 2020; 11(1):5376.
  • Bobillo S, Crespo M, Escudero L, Mayor R, Raheja P, Carpio C, Rubio-Perez C, Tazón-Vega B, Palacio C, Carabia J, Jiménez I, Nieto JC, Montoro J, Martínez-Ricarte F, Castellví J, Simó M, Puigdefàbregas L, Abrisqueta P, Bosch F, Seoane J. Cell free circulating tumor DNA in cerebrospinal fluid detects and monitors central nervous system involvement of B-cell lymphomas. Haematologica. 2020. 106(2):513-521
  • Pascual-García M, Bonfill-Teixidor E, Planas-Rigol E, Rubio-Perez C, Iurlaro R, Arias A, Cuartas I, Sala-Hojman A, Escudero E, Martínez-Ricarte F, Huber-Ruano I, Nuciforo P, Pedrosa L, Marques C, Braña I, Garralda E, Vieito M, Squatrito M, Pineda E, Graus F, Espejo C, Sahuquillo J, Tabernero J, Seoane J. LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8 + T cell tumor-infiltration impairing anti-PD1 therapy. Nat Commun. 2019 Jun 11;10(1):2416.
  • Martínez-Ricarte F, Mayor R, Martínez-Sáez E, Rubio-Pérez C, Pineda E, Cordero E, Cicuéndez M, Poca MA, López-Bigas N, Ramon y Cajal S, Vieito M, Carles J, Tabernero J, Vivancos A, Gallego S, Graus F, Sahuquillo J, Seoane J. Molecular diagnosis of diffuse gliomas through sequencing of cell-free circulating tumour DNA from cerebrospinal fluid. Clin Cancer Res. 2018 Jun 15;24(12):2812-2819.
  • Capdevila J, Mayor R, Mancuso FF, Iglesias C, Caratù G, Matos I, Zafón C, Hernando J, Petit A, Nuciforo P, Cameselle-Teijeiro JM, Álvarez 4, Recio JA, Tabernero J, Matias-Guiu X, Vivancos A, Seoane J. Early evolutionary divergence between papillary and anaplastic thyroid cancers. Ann Oncol. 2018 June 1; 29(6): 1454–1460.
  • Seoane J. Division hierarchy leads to cell heterogeneity. Nature. 2017 Sep 14;549(7671):164-166.
  • Huber-Ruano I, Raventos C, Cuartas I, Sánchez-Jaro C, Wosikowski K, Janicot M, Seoane J. An Antisense oligonucleotide targeting TGF-β2 inhibits lung metastasis and induces CD86 expression in tumor-associated macrophages. Ann Oncol. 2017 Sep 1;28(9):2278-2285
  • Seoane J, Gomis RR. TGFβ Family Signaling in Tumor Suppression and Cancer Progression. Cold Spring Harb Perspect Biol. 2017 Dec 1;9(12).
  • Byrne AT, Alférez DG, Amant F, Annibali D, Arribas J, Biankin AV, Bruna A, Budinská E, Caldas C, Chang DK, Clarke RB, Clevers H, Coukos G, Dangles-Marie V, Eckhardt SG, Gonzalez-Suarez E, Hermans E, Hidalgo M, Jarzabek MA, de Jong S, Jonkers J, Kemper K, Lanfrancone L, Mælandsmo GM, Marangoni E, Marine JC, Medico E, Norum JH, Palmer HG, Peeper DS, Pelicci PG, Piris-Gimenez A, Roman-Roman S, Rueda OM, Seoane J, Serra V, Soucek L, Vanhecke D, Villanueva A, Vinolo E, Bertotti A, Trusolino L. Interrogating open issues in cancer precision medicine with patient-derived xenografts. Nat Rev Cancer. 2017 Apr;17(4):254-268.
  • Gueorguieva I, Cleverly A, Desaiah D, Azaro A, Seoane J, Braña I, Sicart E, Miles C, Lahn MM, Mitchell MI, Rodon J. Relative bioavailability of three formulations of galunisertib administered as monotherapy in patients with advanced or metastatic cancer.  Drugs Context. 2016 Dec 2;5:212303. eCollection 2016.
  • De Mattos-Arruda L, Mayor R, Ng CKY, Weigelt B, Martínez-Ricarte F, Torrejon D, Oliveira M, Arias A, Raventos C, Tang J, Guerini-Rocco E, Martínez-Sáez E, Lois S, Marín O, de la Cruz X, Piscuoglio S, Towers R, Vivancos A, Peg V, Ramon y Cajal S, Carles J, Rodon J, González-Cao M, Tabernero J, Felip E, Sahuquillo J, Berger MF, Cortes J, Reis-Filho JS, Seoane J*. Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nature Communications. 2015; 6:8839. (*corresponding author).
  • Rodon L, Gonzalez-Junca A, Inda MD, Sala-Hojman A, Martinez-Saez E, Seoane J*. Active CREB1 promotes a malignant TGF-β2 autocrine loop in glioblastoma. Cancer Discov. 2014; 4(10):1230-41. (*corresponding author).
  • Serra V, Vivancos A, Puente XS, Felip E, Silberschmidt D, Caratu G, Parra JL, De Mattos-Arruda L, Grueso J, Hernandez-Losa J, Arribas J, Prudkin L, Nuciforo P, Scaltriti M, Seoane J*, Baselga J*. Clinical response to a lapatinib-based therapy of a Li-Fraumeni Syndrome patient with a novel HER2-V659E mutation. Cancer Discov. 2013; 3(11):1238-44 (*co-corresponding authors).
  • Eichhorn PJ, Rodon L, Gonzàlez-Juncà A, Dirac A, Gili M, Martínez-Sáez E, Aura C, Barba I, Peg V., Prat A., Cuartas I, Jimenez J, García-Dorado D, Sahuquillo J, Bernards R, Baselga J, Seoane J. USP15 stabilizes TGF-β receptor I and promotes oncogenesis through the activation of TGF-β signaling in glioblastoma. Nature Medicine 2012;18(3):429-35. [see News and Views: Aggarwal K and Massagué J. Ubiquitin removal in the TGF- β pathway. Nature Cell Biology. 2012;14(7):656-7].
  • Anido J, Sáez-Borderías A, Gonzàlez-Juncà A, Rodón L, Folch G, Carmona MA, Prieto-Sánchez RM, Barba I, Martínez-Sáez E, Prudkin L, Cuartas I, Raventós C, Martínez-Ricarte F, Poca MA, García-Dorado D, Lahn M, Yingling J, Rodón J, Sahuquillo J, Baselga J, Seoane J. TGF-β receptor inhibitors target the CD44high/Id1high glioma-initiating cell population in human glioblastoma. Cancer Cell. 2010;18(6):655-68 [see Preview: Edwards LA, Fine HA. The Ids have it. Cancer Cell. 2010;18(6):543-5.

All publications

  • Cufer T, Kosty MP; Curriculum Development Subgroup—ESMO/ASCO Global Curriculum Working Group. ESMO/ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2023. ESMO Open. 2023 Dec;8(6):101631.
  •  E. Le Rhun, M. Weller, M. van den Bent, D. Brandsma, J. Furtner, R. Rudà, D. Schadendorf, J. Seoane, J.-C. Tonn, P. Wesseling, W. Wick, G. Minniti, S. Peters, G. Curigliano & M. Preusser, on behalf of the EANO Guidelines Committee and ESMO Guidelines Committee. Leptomeningeal metastasis from solid tumours: EANO-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. ESMO Open.  2023; 8(5):101624.
  •  Seoane J. Patient-derived preclinical models to develop immunotherapies. Mol Oncol. 2023 Jul;17(7):1169-1172.      
  •  Hallett RM, Bonfill-Teixidor E, Iurlaro R, Arias A, Raman S, Bayliss P, Egorova O, Neva-Alejo A, McGray AR, Lau E, Bosch A, Beilschmidt M, Maetzel D, Fransson J, Huber-Ruano I, Anido J, Julien JP, Giblin P, Seoane J. Therapeutic Targeting of LIF Overcomes Macrophage-mediated Immunosuppression of the Local Tumor Microenvironment. Clin Cancer Res. 2023 Feb 16;29(4):791-804.
  • Hernando-Calvo A, Vila-Casadesús M, Bareche Y, Gonzalez-Medina A, Abbas-Aghababazadeh F, Lo Giacco D, Martin A, Saavedra O, Brana I, Vieito M, Fasani R, Stagg J, Mancuso F, Haibe-Kains B, Han M, Berche R, Pugh TJ, Mirallas O, Jimenez J, Gonzalez NS, Valverde C, Muñoz-Couselo E, Suarez C, Diez M, Élez E, Capdevila J, Oaknin A, Saura C, Macarulla T, Galceran JC, Felip E, Dienstmann R, Bedard PL, Nuciforo P, Seoane J, Tabernero J, Garralda E, Vivancos A. A pan-cancer clinical platform to predict immunotherapy outcomes and prioritize immuno-oncology combinations in early-phase trials. Med. 2023 Oct 13;4(10):710-727.e5.
  •  Pecharromán I, Solé L, Álvarez-Villanueva D, Lobo-Jarne T, Alonso-Marañón J, Bertran J, Guillén Y, Montoto Á, Martínez-Iniesta M, García-Hernández V, Giménez G, Salazar R, Santos C, Garrido M, Borràs E, Sabidó E, Bonfill-Teixidor E, Iurlaro R, Seoane J, Villanueva A, Iglesias M, Bigas A, Espinosa L. IκB kinase-α coordinates BRD4 and JAK/STAT signaling to subvert DNA damage-based anticancer therapy. EMBO J. 2023 Nov 2;42(21):e114719.
  • Hallett R, Bonfill-Teixidor E, Iurlaro R, Arias A, Raman S, Bayliss PE, Egorova O, Neva-Alejo A, McGray AR, Lau E, Bosch A, Beilschmidt M, Maetzel D, Fransson J, Huber-Ruano I, Anido J, Julien JP, Giblin PA, Seoane J Therapeutic targeting of LIF overcomes macrophage mediated immunosuppression of the local tumor microenvironment. Clin Cancer Res . 2022; Online ahead of print.
  • Iurlaro R, Inja Waldhauer, Ester Planas-Rigol , Ester Bonfill-Teixidor, Alexandra Arias, Valeria Nicolini, Anne Freimoser-Grundschober, Isabel Cuartas, Alba Martínez-Moreno, Francisco Martínez-Ricarte  , Esteban Cordero, Marta Cicuendez, Simona Casalino, Xavier Guardia-Reyes, Linda Fahrni , Thomas Pöschinger , Virginie Steinhart, Marine Richard, Stefanie Briner, Joerg Mueller, Franz Osl, Johannes Sam, Sara Colombetti, Marina Bacac, Christian Klein, Estela Pineda, Luis Reyes-Figueroa, Alberto Di Somma, Josep González, Paolo Nuciforo, Joan Carles, Maria Vieito, Josep Tabernero, Pablo Umaña , Seoane, J. A Novel EGFRvIII T-Cell Bispecific Antibody for the Treatment of Glioblastoma. Mol Cancer Ther . 2022;21(10):1499-1509.
  • Pascual,G. Attard,F.-C. Bidard, G. Curigliano,L. De Mattos-Arruda, M. Diehn, A. Italiano J. Lindberg, J.D. MerkerC. Montagut, N. Normanno, K. Pantel, G. Pentheroudakis, S. Popat, J.S. Reis-Filho, J. Tie , Seoane, J, N. Tarazona, T. Yoshino, N.C. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. Annals of Oncology , 2022; 33(8):750-768.
  • Borazanci ,A. M. Schram, E. Garralda, I. Brana , M. Vieito Villar , A. Spreafico , M. Oliva, N. J. Lakhani , K. Hoffman, R. M. Hallett , D. Maetzel , F. Hua , J. Hilbert , P. Giblin , J. Anido , A. Kelly , P. J. Vickers , R. Wasserman, Seoane, J , L. L. Siu , D. M. Hyman , D. V. Hoff & J. Tabernero. Phase I, first-in-human study of MSC-1 (AZD0171), a humanized anti-leukemia inhibitory factor monoclonal antibody, for advanced solid tumors. Clinical Trial. ESMO Open . 2022, 7(4):100530.
  • Bonfill-Teixidor E, Iurlaro R, Handl C, Wichmann J, Arias A, Cuartas I, Emmenegger J, Romagnani A, Mangano L, Lorber T, Berrera M, Godfried Sie C, Köchl F, Eckmann J, Feddersen R, Kornacker M, Schnetzler G, Cicuéndez M, Cordero E, Topczewski TE, Ferrés-Pijoan A, Gonzalez J, Martínez-Ricarte F, Muñoz-Couselo E, Tabernero J, Bischoff JR, Pettazzoni P, Seoane J. Activity and resistance of a brain-permeable paradox breaker BRAF inhibitor in melanoma brain metastasis. Cancer Res . 2022, 18;82(14):2552-2564.
  • Soffietti R, Bettegowda C, Mellinghoff IK, Warren KE, Ahluwalia MS, De Groot JF, Galanis E, Gilbert MR, Jaeckle KA, Le Rhun E, Rudà R, Seoane J, Thon N, Umemura Y, Weller M, van den Bent MJ, Vogelbaum MA, Chang SM, Wen PY. Liquid biopsy in gliomas: a RANO review and proposals for clinical applications. Neuro Oncology . 2022, 1;24(6):855-871
  • Seoane J, Escudero L. Cerebrospinal fluid liquid biopsies for medulloblastoma. Nature Reviews Clinical Oncology . 2022;19(2):73-74.
  • Gulley JL, Schlom J, Barcellos-Hoff MH, Wang XJ, Seoane J, Audhuy F, Lan Y, Dussault I, Moustakas A. Dual inhibition of TGF-β and PD-L1 as a novel cancer treatment approach. Molecular Oncology. 2022;16(11):2117-2134.
  • Soffietti R, Bettegowda C, Mellinghoff IK, Warren KE, Ahluwalia MS, De Groot JF, Galanis E, Gilbert MR, Jaeckle KA, Le Rhun E, Rudà R, Seoane J, Thon N, Umemura Y, Weller M, van den Bent MJ, Vogelbaum MA, Chang SM, Wen PY. Liquid biopsy in gliomas: a RANO review and proposals for clinical applications. Neuro Oncol. 2022. (Online ahead of print).
  • Seoane J, Escudero L. Cerebrospinal fluid liquid biopsies for medulloblastoma. Nature Reviews Clinical Oncology. 2022;19(2):73-74.
  • Gulley JL, Schlom J, Barcellos-Hoff MH, Wang XJ, Seoane J, Audhuy F, Lan Y, Dussault I, Moustakas A. Dual inhibition of TGF-β and PD-L1 as a novel cancer treatment approach. Molecular Oncology.2021. (Online ahead of print).
  • Nieto P, Elosua-Bayes M, Trincado JL, Marchese D, Massoni-Badosa R, Salvany M, Henriques A, Nieto J, Aguilar-Fernández S, Mereu E, Moutinho C, Ruiz S, Lorden P, Chin VT, Kaczorowski D, Chan CL, Gallagher R, Chou A, Planas-Rigol E, Rubio-Perez C, Gut I, Piulats JM, Seoane J, Powell JE, Batlle E, Heyn H. A single-cell tumor immune atlas for precision oncology. Genome Res. 2021; (10):1913-1926.
  • Le Rhun E, Guckenberger M, Smits M, Dummer R, Bachelot T, Sahm F, Galldiks N, de Azambuja E, Berghoff AS, Metellus P, Peters S, Hong Y-K, Winkler F, Schadendorf D, van den Bent M, Seoane J, Stahel R, Minniti G, Wesseling P, Weller M & Preusser M on behalf of the EANO Executive Board and ESMO Guidelines Committee*. EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumors. Annals of Oncology. 2021; 32(11): 1332-1347.
  • Escudero L , Martínez-Ricarte F, Seoane J. ctDNA-Based Liquid Biopsy of Cerebrospinal Fluid in Brain Cancer. Cancers. 2021; 13 (9):1989.
  • Rubio-Perez C, Planas-Rigol E, Trincado JL, Bonfill-Teixidor E, Arias A, Marchese D, Moutinho C, Serna G, Pedrosa L, Iurlaro R, Martínez-Ricarte F, Escudero L, Cordero E, Cicuendez M, Ruiz S, Parra G, Nuciforo P, Gonzalez J, Pineda E, Sahuquillo J, Tabernero J, Heyn H*, Seoane J*. Immune cell profiling of the cerebrospinal fluid enables the characterization of the brain metastasis microenvironment. Nature Communications. 2021 (Epub ahead of print).
  • Milena Cribiù F, Erra R, Pugni L, Rubio Perez C, Alonso L, Simonetti S, Croci GA, Serna G, Ronchi A, Pietrasanta C, Lunghi G, Fagnani AM, Pinana M, Matter M, Tzankov A, Terracciano L, Anton Pagarolas A, Ferrazzi E, Ferrero S, Iurlaro E, Seoane J*, Nuciforo P*. Severe SARS-CoV-2 placenta infection can impact neonatal outcome in the absence of vertical transmission. (*co-corresponding authors). Journal of Clinical Investigation. 2021 (Epub ahead of print).
  • Galson JD, Schaetzle S, Bashford-Rogers RJM, Raybould MIJ, Kovaltsuk A, Kilpatrick GJ, Minter R, Finch DK, Dias J, James LK, Thomas G, Jason Lee WY, Betley J, Cavlan O, Leech A, Deane CM, Seoane J, Caldas C, Pennington DJ, Pfeffer PE, Osbourn J. Deep sequencing of B cell receptor repertoires from COVID-19 patients reveals strong convergent immune signatures. Frontiers in Immunology. 2020; 11:605170.
  • Ligero Hernández M, Garcia Ruiz A, Viaplana C, Villacampa Javierre G, Raciti MV, Landa J, Matos I, Martin Liberal JJ, Ochoa de Olza M, Hierro C, Mateo J, Gonzalez Rodriguez M, Morales R, Suárez C, Rodon J, Élez E, Braña I, Muñoz Couselo E, Oaknin A, Fasani R, Nuciforo P, Gil D, Rubio-Pérez C, Seoane J, Felip E, Escobar M, Tabernero J, Carles J, Dienstmann R, Garralda E, Perez Lopez R. A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors. Radiology. 2021 Epub ahead of print.
  • Puyol M, Seoane J, Aguilar E, Vozza LB, Orbe I, Crawford KH, Fernández A, Bray F, Johnson SE, Gopal S. WORLD CANCER RESEARCH DAY: A call to action for a coordinated international research effort to prevent, diagnose and treat cancer. Clinical Cancer Research. 2021. 27(4):963-966.
  • Escudero L, Martínez-Ricarte F, Seoane J. Cerebrospinal fluid circulating tumour DNA as a liquid biopsy for central nervous system malignancies. Current Opinion Neurology. 2020; 33(6):736-741.
  • Escudero L, Llort A, Arias A, Diaz-Navarro A, Martínez-Ricarte F, Rubio-Perez C, Mayor R, Caratú G, Martínez-Sáez E, Vázquez-Méndez É, Lesende-Rodríguez I, Hladun R, Gros L, Ramón y Cajal S, Poca M, Puente X, Sahuquillo J, Gallego S, Seoane J. Circulating tumour DNA from the cerebrospinal fluid allows the characterisation and monitoring of medulloblastoma. Nature Communications. 2020; 11(1):5376.
  • Jiménez, I, Carabia J, Bobillo S, Palacio C, Abrisqueta P, Pagès C, Nieto JC, Castellví J, Martínez‑Ricarte F, Escoda L, Perla C, Céspedes-Torrez DH, Boix J, Purroy N, Puigdefàbregas L, Seoane J, Bosch F, Crespo M. Repolarization of tumor infiltrating macrophages and increased survival in mouse primary CNS lymphomas after XPO1 and BTK inhibition. Journal of Neuro-Oncology. 2020; 149(1):13-25.
  • Ciardiello D, Elez ME, Tabernero J, Seoane J. Clinical development of therapies targeting TGFβ: current knowledge and future perspectives. Annals of Oncology. 2020. 31 (10):1336 – 1349.
  • Le Rhun E, Seoane J, Salzet M, Soffietti R, Weller M. Liquid biopsies for diagnosing and monitoring primary tumors of the central nervous system. Cancer letters. 2020; 480:24-28.
  • Seoane J. Immunotherapy Research: today’s science is tomorrow’s medicine. The Innovation Platform. 2020; 1: 122-123.
  • Bobillo S, Crespo M, Escudero L, Mayor R, Raheja P, Carpio C, Rubio-Perez C, Tazón-Vega B, Palacio C, Carabia J, Jiménez I, Nieto JC, Montoro J, Martínez-Ricarte F, Castellví J, Simó M, Puigdefàbregas L, Abrisqueta P, Bosch F, Seoane J. Cell free circulating tumor DNA in cerebrospinal fluid detects and monitors central nervous system involvement of B-cell lymphomas. Haematologica. 2020. 106(2):513-521
  • Gargini R*, Segura-Collar B*, Herránz B, Garcia-Escudero V, Romero-Bravo A, Núñez FJ, García-Pérez D, Gutiérrez-Guamán J, Ayuso-Sacido A, Seoane J, Pérez-Núñez A, Sepúlveda-Sánchez JM, Hernández-Laín A, Castro MG, García-Escudero R, Ávila J, Sánchez-Gómez P. The IDH-TAU-EGFR triad defines the neovascular landscape of diffuse gliomas. Science Translational Medicine. 2020; 12(527)
  • Janin M, Ortiz-Barahona V, de Moura MC, Martínez-Cardús A, Llinàs-Arias P, Soler M, Nachmani D, Pelletier J, Schumann U, Calleja-Cervantes ME, Moran S, Guil S, Bueno-Costa A, Piñeyro D, Perez-Salvia M, Rosselló-Tortella M, Piqué L, Bech-Serra JJ, De La Torre C, Vidal A, Martínez-Iniesta M, Martín-Tejera JF, Villanueva A, Arias A, Cuartas I, Aransay AM, La Madrid AM, Carcaboso AM, Santa-Maria V, Mora J, Fernandez AF, Fraga MF, Aldecoa I, Pedrosa L, Graus F, Vidal N, Martínez-Soler F, Tortosa A, Carrato C, Balañá C, Boudreau MW, Hergenrother PJ, Kötter P, Entian KD, Hench J, Frank S, Mansouri S, Zadeh G, Dans PD, Orozco M, Thomas G, Blanco S, Seoane J, Preiss T, Pandolfi PP, Esteller M. Epigenetic loss of RNA-methyltransferase NSUN5 in glioma targets ribosomes to drive a stress adaptive translational program. Acta Neuropathologica. 2019;138(6):1053-1074.
  • Seoane J. Beyond blood with liquid biopsies. ESMO Perspectives. 2019 August 30.
  • Siravegna G, Mussolin B, Venesio T, Marsoni S, Seoane J, Dive C, Papadopoulos N, Kopetz S, Corcoran R. B, Siu L. L, and Bardelli A. How liquid biopsies can change clinical practice in oncology. Annals of Oncology. 2019; 30(10):1580-1590.
  • Pascual-GarcíaM, Bonfill-TeixidorE, Planas-RigolE, Rubio-PerezC, IurlaroR,AriasA, Cuartas I, Sala-HojmanA, Escudero E, Martínez-Ricarte F, Huber-Ruano I, NuciforoP, PedrosaL, MarquesC, BrañaI, GarraldaE, VieitoM, SquatritoM, PinedaE, GrausF, EspejoC, SahuquilloJ, TaberneroJ, Seoane J. LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8+T cell tumor-infiltration impairing anti-PD1 therapy. Nat Commun. 2019 Jun 11;10(1):2416.
  • Seoane J, De Mattos-ArrudaL, Le RhunE, BardelliA, WellerM. Cerebrospinal fluid cell-free tumour DNA as a liquid biopsy for primary brain tumours and central nervous system metastases. Ann Oncol. 2019 Feb 1;30(2):211-218.
  • Siravegna G, Mussolin B, Venesio T, Marsoni S, Seoane J, Dive C, Papadopoulos N, Kopetz S, Corcoran RB, Siu LL, Bardelli A. How liquid biopsies can change clinical practice in oncology. Ann Oncol. 2019 Oct 1;30(10):1580-1590.
  • De Mattos-Arruda L, Sammut SJ, Ross EM, Bashford-Rogers R, Greenstein E, Markus H, Morganella S, Teng Y, Maruvka Y, Pereira B, Rueda OM, Chin SF, Contente-Cuomo T, Mayor R, Arias A, Ali HR, Cope W, Tiezzi D, Dariush A, Dias Amarante T, Reshef D, Ciriaco N, Martinez-Saez E, Peg V, Ramon Y Cajal S, Cortes J, Vassiliou G, Getz G, Nik-Zainal S, Murtaza M, Friedman N, Markowetz F, Seoane J, Caldas C. The Genomic and Immune Landscapes of Lethal Metastatic Breast Cancer. Cell Rep. 2019 May 28;27(9):2690-2708.
  • Seoane J. Division hierarchy leads to cell heterogeneity. Nature. 2017 Sep 14;549(7671):164-166.
  • Huber-Ruano I, Raventos C, Cuartas I, Sánchez-Jaro C, Wosikowski K, Janicot M, Seoane J. An Antisense oligonucleotide targeting TGF-β2 inhibits lung metastasis and induces CD86 expression in tumor-associated macrophages. Ann Oncol. 2017 Sep 1;28(9):2278-2285
  • Seoane J, Gomis RR. TGFβ Family Signaling in Tumor Suppression and Cancer Progression. Cold Spring Harb Perspect Biol. 2017 Dec 1;9(12).
  • Byrne AT, Alférez DG, Amant F, Annibali D, Arribas J, Biankin AV, Bruna A, Budinská E, Caldas C, Chang DK, Clarke RB, Clevers H, Coukos G, Dangles-Marie V, Eckhardt SG, Gonzalez-Suarez E, Hermans E, Hidalgo M, Jarzabek MA, de Jong S, Jonkers J, Kemper K, Lanfrancone L, Mælandsmo GM, Marangoni E, Marine JC, Medico E, Norum JH, Palmer HG, Peeper DS, Pelicci PG, Piris-Gimenez A, Roman-Roman S, Rueda OM, Seoane J, Serra V, Soucek L, Vanhecke D, Villanueva A, Vinolo E, Bertotti A, Trusolino L. Interrogating open issues in cancer precision medicine with patient-derived xenografts. Nat Rev Cancer. 2017 Apr;17(4):254-268.
  • Gueorguieva I, Cleverly A, Desaiah D, Azaro A, Seoane J, Braña I, Sicart E, Miles C, Lahn MM, Mitchell MI, Rodon J. Relative bioavailability of three formulations of galunisertib administered as monotherapy in patients with advanced or metastatic cancer.  Drugs Context. 2016 Dec 2;5:212303. eCollection 2016.
  • Seoane J. The Taming of the TAMs. Trends Cell Biol. 2016 Aug;26(8):562-3.
  • Gomis R, Seoane J. TGFβ Family Signaling in Tumor Suppression and Cancer Progression. Cold Harbor 2016. In press 2016
  • Byrne A, Alferez D, Amant F, Annibali D, Arribas J, Biankin A, Bruna A, Budinská E, Caldas C, Chang D, Clarke R, Clevers H, Coukos G, Dangles-Marie V, Eckhardt SG, Gonzalez-Suarez E, Hermans E, Hidalgo M, Jarzabek M, de Jong S, Jonkers J, Kemper K, Lanfrancone L, Mælandsmo GM, Marangoni E, Marine JC, Medico E, Norum JH, Palmer H, Peeper D, Pelicci PG, Piris A, Roman-Roman S, Rueda O, Seoane J, Serra V, Soucek L, Vanhecke D, Villanueva A, Vinolo E, Bertotti A, Trusolino L. Interrogating open issues in oncology and cancer precision medicine using Patient-Derived Xenograft models. Nature Review Cancer. In Press 2016
  • Gueorguieva I, Cleverly A, Desaiah D, Azaro A, Seoane J, Braña I, et al. Drugs in Context 2016; 5:201303. “Relative bioavailability of three formulations of galunisertib administered as monotherapy in patients with advanced or metastatic cancer”, Drugs in Context, 2016; 5: 201303. DOI: 10.7573/dic.212303
  • Seoane J. The Taming of the TAMs. Trends in Cell Biology. Aug;26(8):562-3. doi: 10.1016/j.tcb.2016.06.007. Epub 2016 Jul 6.
  • De Mattos-Arruda L, Mayor R, Ng CKY, Weigelt B, Martínez-Ricarte F, Torrejon D, Oliveira M, Arias A, Raventos C, Tang J, Guerini-Rocco E, Martínez-Sáez E, Lois S, Marín O, de la Cruz X, Piscuoglio S, Towers R, Vivancos A, Peg V, Ramon y Cajal S, Carles J, Rodon J, González-Cao M, Tabernero J, Felip E, Sahuquillo J, Berger MF, Cortes J, Reis-Filho JS, Seoane J*. Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nature Communications. 2015; 6:8839. (*corresponding author).
  • De Mattos-Arruda L, Bottai G, Nuciforo PG, Di Tommaso L, Giovannetti E, Peg V, Losurdo A, Pérez-Garcia J, Masci G, Corsi F, Cortés J, Seoane J, Calin GA, Santarpia L. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients. Oncotarget. 2015;6(35):37269-80.
  • Brastianos PK, Carter SL, Santagata S, Cahill DP, Taylor-Weiner A, Jones RT, Van Allen EM, Lawrence MS, Horowitz PM, Cibulskis K, Ligon KL, Tabernero J, Seoane J, Martinez-Saez E, Curry WT, Dunn IF, Paek SH, Park SH, McKenna A, Chevalier A, Rosenberg M, Barker FG 2nd, Gill CM, Van Hummelen P, Thorner AR, Johnson BE, Hoang MP, Choueiri TK, Signoretti S, Sougnez C, Rabin MS, Lin NU, Winer EP, Stemmer-Rachamimov A, Meyerson M, Garraway L, Gabriel S, Lander ES, Beroukhim R, Batchelor TT, Baselga J, Louis DN, Getz G, Hahn WC. Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. Cancer Discov. 2015;5(11):1164-77
  • Iyengar PV, Jaynes P, Rodon L, Lama D, Law KP, Lim YP, Verma C, Seoane J, Eichhorn PJ. USP15 regulates SMURF2 kinetics through C-lobe mediated deubiquitination. Sci Rep. 2015;5:14733.
  • Ulloa F, Gonzàlez-Juncà A, Meffre D, Barrecheguren PJ, Martínez-Mármol R, Pazos I, Olivé N, Cotrufo T, Seoane J, Soriano E. Blockade of the SNARE Protein Syntaxin 1 Inhibits Glioblastoma Tumor Growth. PLoS One. 2015;10(3):e0119707.
  • Rodon J, Carducci MA, Sepulveda-Sanchez JM, Azaro A, Calvo E, Seoane J, Brana I, Sicart E, Gueorguieva I, Cleverly AL, Sokalingum Pillay N, Desaiah D, Estrem ST, Paz-Ares L, Holdoff M, Blakeley J, Lahn MM, Baselga J. First-in-Human Dose Study of the Novel Transforming Growth Factor-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma. Clin Cancer Res. 2015;21(3):553-60.
  • Rodon J, Carducci M, Sepulveda-Sánchez JM, Azaro A, Calvo E, Seoane J, Braña I, Sicart E, Gueorguieva I, Cleverly A, Pillay NS, Desaiah D, Estrem ST, Paz-Ares L, Holdhoff M, Blakeley J, Lahn MM, Baselga J. Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer. Invest New Drugs. 2015;33(2):357-70.
  • Seoane J*, De Mattos-Arruda L. Escaping out of the brain. Cancer Discov. 2014;4(11):1259-61. (*corresponding author)
  • Hidalgo M, Amant F, Biankin AV, Budinská E, Byrne AT, Caldas C, Clarke RB, de Jong S, Jonkers J, Mælandsmo GM, Roman-Roman S, Seoane J, Trusolino L, Villanueva A. Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research. Cancer Discov. 2014;4(9):998-1013.
  • Henderson D, Ogilvie LA, Hoyle N, Keilholz U, Lange B, Lehrach H on behalf of the OncoTrack Consortium. Personalized medicine approaches for colon cancer driven by genomics and systems biology: OncoTrack. Biotechnol J. 2014;9(9):1104-14.
  • Rodon L, Gonzalez-Junca A, Inda MD, Sala-Hojman A, Martinez-Saez E, Seoane J*. Active CREB1 promotes a malignant TGF-β2 autocrine loop in glioblastoma. Cancer Discov. 2014;4(10):1230-41. (*corresponding author)
  • Annibali D, Whitfield JR, Favuzzi E, Jauset T, Serrano E, Cuartas I, Redondo-Campos S, Folch G, Gonzalez-Juncà A, Sodir NM, Masso-Vallés D, Beaulieu ME, Swigart LB, Mc Gee MM, Somma MP, Nasi S, Seoane J, Evan GI, Soucek L. Myc inhibition is effective against glioma and reveals a role for Myc in mitosis. Nature Communications. 2014;5:4632.
  • De Mattos-Arruda L, Weigelt B, Cortes J, Won HH, Ng CK, Nuciforo P, Bidard FC, Aura C, Saura C, Peg V, Piscuoglio S, Oliveira M, Smolders Y, Patel P, Norton L, Tabernero J, Berger MF, Seoane J, Reis-Filho JS. Capturing Intra-Tumor Genetic Heterogeneity by De Novo Mutation Profiling of Circulating Cell-Free Tumor DNA: A Proof-of-Principle. Ann Oncol. 2014;25(9):1729-35.
  • Martino-Echarri E, Fernández-Rodríguez R, Bech-Serra JJ, Plaza-Calonge MC, Vidal N, Casal C, Colomé N, Seoane J*, Canals F, Rodríguez-Manzaneque JC. Relevance of IGFBP2 proteolysis in glioma and contribution of the extracellular protease ADAMTS1. Oncotarget. 2014;5(12):4295-304. (*corresponding author)
  • Seoane J. Gremlins Sabotage the Mechanisms of Cancer Stem Cell Differentiation. Cancer Cell. 2014;25(6):716-7.
  • Seoane J*, De Mattos-Arruda L. Brain metastasis: new opportunities to tackle therapeutic resistance. Review Article, Mol Oncol. 2014;8(6):1120-31. (*corresponding author).
  • Seoane J*, De Mattos-Arruda L. The challenge of intratumour heterogeneity in precision medicine. J Intern Med. 2014;276(1):41-51. (*corresponding author)
  • Inda MD, Bonavia R, Seoane J*. Glioblastoma multiforme: a look inside its heterogeneous nature. Cancers (Basel). 2014;6(1):226-39. (*co-corresponding author).
  • Cortés J, Calvo E, Vivancos A, Perez-Garcia J, Recio JA, Seoane J. New approach to cancer therapy based on a molecularly defined cancer classification. CA-Cancer J Clin. 2014;64(1):70-4.
  • De Mattos-Arruda L, Bidard FC, Won HH, Cortes J, Ng CK, Peg V, Nuciforo P, Jungbluth AA, Weigelt B, Berger MF, Seoane J*, Reis-Filho JS. Establishing the origin of metastatic deposits in the setting of multiple primary malignancies: The role of massively parallel sequencing. Mol Oncol. 2014;8(1):150-8 (*co-corresponding authors).
  • Serra V, Vivancos A, Puente XS, Felip E, Silberschmidt D, Caratu G, Parra JL, De Mattos-Arruda L, Grueso J, Hernandez-Losa J, Arribas J, Prudkin L, Nuciforo P, Scaltriti M, Seoane J*, Baselga J*. Clinical response to a lapatinib-based therapy of a Li-Fraumeni Syndrome patient with a novel HER2-V659E mutation. Cancer Discov. 2013;3(11):1238-44 (*co-corresponding authors).
  • De Mattos-Arruda L, Cortes J, Santarpia L, Vivancos A, Tabernero J, Reis-Filho JS, Seoane J. Circulating Tumor Cells and Cell-Free DNA as Tools for Managing Breast Cancer. Nature Reviews. Clinical Oncology. 2013;10(7):377-89.
  • De Mattos-Arruda L, Tabernero J, Seoane J, Cortes J. Circulating tumour cells in early breast cancer. Lancet Oncol. 2012;13(9):e370.
  • Ros-Blanco L, Anido J, Bosser R, Este J, Clotet B, Kosoy A, Ruiz-Avila L, Teixido J, Seoane J*, Borrell JI. NonCyclam Tetraamines inhibit CXC Chemokine Receptor Type 4 and target Glioma-Initiating Cells. J Med Chem. 2012;55(17):7560-70 (*co-corresponding author).
  • Eichhorn PJ, Rodon L, Gonzàlez-Juncà A, Dirac A, Gili M, Martínez-Sáez E, Aura C, Barba I, Peg V., Prat A., Cuartas I, Jimenez J, García-Dorado D, Sahuquillo J, Bernards R, Baselga J, Seoane J. USP15 stabilizes TGF-β receptor I and promotes oncogenesis through the activation of TGF-β signaling in glioblastoma. Nature Medicine 2012;18(3):429-35. [see News and Views: Aggarwal K and Massagué J. Ubiquitin removal in the TGF- β pathway. Nature Cell Biology. 2012;14(7):656-7].
  • Anido J, Sáez-Borderías A, Gonzàlez-Juncà A, Rodón L, Folch G, Carmona MA, Prieto-Sánchez RM, Barba I, Martínez-Sáez E, Prudkin L, Cuartas I, Raventós C, Martínez-Ricarte F, Poca MA, García-Dorado D, Lahn M, Yingling J, Rodón J, Sahuquillo J, Baselga J, Seoane J. TGF-β receptor inhibitors target the CD44high/Id1high glioma-initiating cell population in human glioblastoma. Cancer Cell. 2010;18(6):655-68 [see Preview: Edwards LA, Fine HA. The Ids have it. Cancer Cell. 2010;18(6):543-5.
  • Seoane J. NO Signals from the Cancer Stem Cell Niche. Cell Stem Cell. 2010;6(2):97-8.
  • Seoane J. TGF-β and cancer initiating cells. Cell Cycle. 2009;8(23):3787-8.
  • Santamaria-Martínez A, Barquinero J, Barbosa-Desongles A, Hurtado A, Pinós T, Seoane J, Poupon MF, Morote J, Reventós J, Munell F. Identification of multipotent mesenchymal stromal cells in the reactive stroma of a prostate cancer xenograft by side population analysis. Exp Cell Res. 2009 ;315(17):3004-13.
  • Peñuelas S, Anido J, Prieto-Sánchez RM, Folch G, Barba I, Cuartas I, García-Dorado D, Poca MA, Sahuquillo J, Baselga J, Seoane J. TGF-β increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma. Cancer Cell. 2009;15(4):315-27 [see Preview: Fine HA. Glioma stem cells: not all created equal. Cancer Cell. 2009;15(4):247-9].
  • Eichhorn PJ, Gili M, Scaltriti M, Serra V, Guzman M, Nijkamp W, Beijersbergen RL, Valero V, Seoane J, Bernards R, Baselga J. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3- kinase inhibitor NVP-BEZ235. Cancer Res. 2008;68(22):9221-30.
  • Seoane J. The TGF-β pathway as a therapeutic target in cancer. Clin Transl Oncol. 2008;10(1):14-19.
  • Baselga J, Rothenberg ML, Tabernero J, Seoane J, Daly T, Cleverly A, Berry B, Rhoades SK, Ray CA, Fill J, Farrington DL, Anne L, Yingling JM, Lahn M, Arteaga C, Carducci M. TGF-β signaling related markers in cancer patients with bone metastasis. Biomarkers. 2008;13(2):217-36.
  • Seoane J. TGF-β signaling in homeostasis and cancer. In: Jakowlew SB (ed.) Cancer Drug Discovery and Development: Transforming Growth Factor-Beta in Cancer Therapy, Vol. 1: Basic and Clinical Biology . 1st ed. Totowa, NJ: Humana Press; 2008. pp 23-35.
  • Bruna A, Darken RS, Rojo F, Ocaña A, Peñuelas S, Arias A, Paris R, Tortosa A, Mora J, Baselga J, Seoane J. High TGF-β-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. Cancer Cell. 2007;11,147-160 [see Preview: Kesari S, Jackson-Grusby L, Stiles CD. “Smad”eningly erratic: target gene methylation determines whether TGFbeta promotes or suppresses malignant glioma. Dev Cell. 2007;12(3):324-5.].
  • Gomis RR, Alarcón C, He W, Wang Q, Seoane J, Lash A and Massagué J. A FoxO-Smad synexpression group in human keratinocytes. P Natl Acad Sci USA. 2006;103(34):12747-52.
  • Seoane J. Escaping from the TGF-β anti-proliferative control. Carcinogenesis. 2006;27(11):2148-56.
  • Massagué J, Seoane J, Wotton D. Smad Transcription Factors. Gene Dev. 2005;19,2783-2810.
  • Seoane J, Le H-V, Shen L, Anderson SA, Massagué J. Integration of Smad and Forkhead Pathways in the Control of Neuroepithelial and Glioblastoma Cell Proliferation. Cell. 2004;117,211-223 (Cover) [see Preview: Arden KC. FoxO: Linking new signaling pathways. Mol Cell. 2004;14(4):416-8].
  • Seoane J. p21(WAF1/CIP1) at the Switch Between the Anti-Oncogenic and Oncogenic Faces of TGF-β. Cancer Biol Ther. 2004;3(2):226-7.
  • Calonge J, Seoane J, Massagué J. Opposite Smad and chicken ovalbumin upstream promoter transcription factor inputs in the regulation of the collagen VII gene promoter by transforming growth factor-β. J Biol Chem. 2004;279(22):23759-65.
  • Seoane J, Le H-V, Massagué J. Myc suppression of p21Cip1 Cdk inhibitor determines the outcome of the p53 response to DNA damage. Nature. 2002;419(6908):729-34 [see Preview: Vousden KH. Switching from life to death: the Miz-ing link between Myc and p53. Cancer Cell. 2002;2(5):351-2].
  • Wu J-W, Hu M, Chai J, Seoane J, Huse M, Li C, Kyin S, Fairman R, Muir TW, Massague J, Shi Y. Crystal structure of a phosphorylated Smad2: Recognition of phosphoserine by the MH2 domain and insights on Smad function in TGF-β signaling. Mol Cell. 2001;8(6):1277-89.
  • Seoane J, Pouponnot C, Staller P, Schader M, Eilers M, Massagué J. TGF-β influences Myc, Miz-1 and Smad to control the CDK inhibitor p15Ink4b. Nature Cell Biology. 2001;3(4):400-8.
  • Staller P, Peukert K, Kiermaier A, Seoane J, Lukas J, Karsunky H, Moroy T, Bartek J, Massagué J, Hanel F, Eilers M. Repression of p15Ink4b expression by Myc through association with Miz-1. Nature Cell Biology. 2001;3,392-399.
  • Hata A, Seoane J, Lagna G, Montalvo E, Hemmati-Brivanlou A, Massagué J.  OAZ uses distinct DNA- and protein-binding zinc fingers in separate BMP-Smad and Olf signaling pathways. Cell. 2000;100(2):229-40.
  • De la Iglesia N, Mukhtar M, Seoane J, Guinovart JJ, Agius L. The role of the regulatory protein of glucokinase in the glucose sensory mechanism of the hepatocyte. J Biol Chem. 2000;275(14):10597-603.
  • Warner BJ, Blain SW, Seoane J, Massagué J. Myc downregulation by transforming growth factor beta required for activation of the p15 Ink4b G1 arrest pathway. Mol Cell Biol. 1999;19(9):5913-22.
  • Seoane J, Barberà A, Telemaque-Potts S, Newgard SB, Guinovart JJ. Glucokinase overexpression restores glucose utilization and storage in cultured hepatocytes from male zucker diabetic fatty rats. J Biol Chem. 1999;274(45):31833-8.
  • Seoane J, Trinh K, O’Doherty RM, Gómez-Foix AM, Lange AJ, Newgard CB, Guinovart JJ. Metabolic impact of adenovirus-mediated overexpression of the glucose 6-phosphatase catalytic subunit in hepatocytes. J Biol Chem. 1997;272(43):26972-7.
  • Guinovart JJ, Gómez-Foix AM, Seoane J, Fernández-Novell JM, Bellido D, Vilaró S. Bridging the gap between glucose phosphorylation and glycogen synthesis in the liver. Biochem Soc T. 1997;25(1):157-60.
  • Seoane J, Gómez-Foix AM, O´Doherty RM, Gómez-Ara C, Newgard CB, Guinovart JJ. Glucose 6-phosphate produced by glucokinase, but not hexokinase I, promotes the activation of hepatic glycogen synthase. J Biol Chem. 1996;271(39):23756-60.
  • O’Doherty RM, Lehman DL, Seoane J, Gómez-Foix AM, Guinovart JJ, Newgard CB. Differential metabolic effects of adenovirus-mediated glucokinase and hexokinase I overexpression in rat primary hepatocytes. J Biol Chem. 1996;271(34):20524-30.

Projects

Grantor: JBID PROJECT ASTRAZENECA
Title: Generate a novel of patient-derived ex vivo tumor platform that recapitulates the native tumor microenvironment of cancer patients.
Role in the Project: Principal Investigator |2023-2026

Grantor: Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) Servei General de Recerca (SGR).
Title: GNOT (Grup de Neuro-Oncologia Translacional).
Project reference: 2021SG 01485
Role in the Project: Principal Investigator |2023-2026

Grantor: ISCIII
Title: Exploring the feasibility of predictive and pharmacodynamics biomarkers of immunotherapy in solid tumors (Immune-4ALL).
Project reference: PMP22/00054
Role in the Project: Principal Investigator | 2023-2026

Grantor: ISCIII-FIS
Title: Estudio del microambiente inmunosupresor del tumor cerebral.
Project reference: PI22/00130
Role in the Project: Principal Investigator | 2023-2025

Grantor:  TRANSCAN-3
Title: Next generation cancer immunotherapy: targeting the tumour microenvironment.
Role in the Project: Principal Investigator | 2022-2025

Grantor: Fundación BBVA
Title: 2nd BBVA Foundation Comprehensive Program of Cancer Immunotherapy & Immunology.
Role in the Project: Principal Investigator | 2022-2025

Grantor: ROCHE
Title: Investigating the activity of a novel small molecule anticancer agent in PDX derived from MSI-H patients progressive to immunotherapies.
Role in the Project: Principal Investigator | 2022-2023

Other projects:

Title: Estudio del microambiente inmunosupresor del tumor cerebral.

Project Reference: PI19/00318.
Role in the Project: Principal Investigator.
Grantor: ISCIII-PFIS
Duration: 2020-2022.

Title: Identification of novel immunotherapeutic targets in lung and melanoma brain metastases.

Role in the Project: Principal Investigator.
Grantor: Fundación ARECES.
Duration: 2019-2022.

Title: Contrato predoctoral de formación en investigación en salud.
Project Reference: FI17/00345.
Role in the Project: Principal investigator.

Duration: 2018-2021.

Grantor: ISCIII-PFIS.

Title: Study of the molecular mechanisms involved in primary (glioblastoma) and secondary (metastasis) brain tumors to identify novel therapeutic targets and anti-cancer agents, biomarkers to select treatments and novel non-invasive methods for molecular diagnosis.
Project Reference: GCTRA16015SEDA.
Role in the Project: Principal Investigator.

Grantor: Fundación Científica de la AECC.
Duration: 2017-2022.

Caracterización molecular de los tumores cerebrales pediátricos mediante el estudio del DNA circulante en sangre y líquido cefalorraquídeo – Fundación FERO

Identificación de mecanismos de resistencia a tratamiento a través del estudio de la evolución de la heterogeneidad intra-tumoral en glioblastoma – Instituto de Salud Carlos III

Programa joves i ciència-Laboratori Joan Seoane – Fundació Catalunya La Pedrera

Desarrollo de un fármaco innovador y personalizado para el tratamiento del cáncer que reactiva el sistema inmune contra el tumor y elimina las células madre tumorales (expediente: RTC-2015-3771-1)
Proyecto financiado por el Ministerio de Economía y Competitividad

El presente proyecto está cofinanciado por el Fondo Europeo de Desarrollo Regional. Objetivo Temático: Promover el desarrollo tecnológico, la innovación y una investigación de calidad.

Tittle: Early molecular nanoDIAGnostics of Brain tumors using Immune-PET (DIAGBI)

Call: Proyectos I+D+i en «líneas estratégicas» 2021

Proyecto PLEC2021-008034, financiado por MCIN/AEI/10.13039/501100011033 y por la Unión Europea NextGenerationEU/PRTR”, para el qual se ha otorgado una ayuda en forma de subvención por un importe total de 170.139,00€

IP: Joan Seoane

Tittle: Biopsia Líquida para la caracterización y monitorización de la metástasis leptomeníngea.

FUNDACION CONTIGO

IP: Joan Seoane

Tittle: Biopsia Líquida para la caracterización y monitorización de la metástasis leptomeníngea.

FUNDACION CONTIGO

IP: Joan Seoane

Tittle: Research Proposal: Generate a novel of patient-derived ex vivo tumor platform that recapitulates the native tumor microenvironment of cancer patients.

JBID PROJECT ASTRAZENECA

2023-2026

IP: Joan Seoane

Title: GNOT (Grup de Neuro-Oncologia Translacional).

Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) Servei General de Recerca (SGR).. Project reference: 2021SG 01485

Role in the Project: Principal Investigator |2023-2026

Title: Exploring the feasibility of predictive and pharmacodynamics biomarkers of immunotherapy in solid tumors (Immune-4ALL).

Grantor: ISCIII- Project reference: PMP22/00054

Role in the Project: Principal Investigator | 2023-2026

Title: Estudio del microambiente inmunosupresor del tumor cerebral.

Grantor: ISCIII-FIS -Project reference: PI22/00130

Role in the Project: Principal Investigator | 2023-2025

Title: Next generation cancer immunotherapy: targeting the tumour microenvironment.

Grantor:  TRANSCAN-3

Role in the Project: Principal Investigator | 2022-2025

Title: 2nd BBVA Foundation Comprehensive Program of Cancer Immunotherapy & Immunology.

Grantor: BBVA

Role in the Project: Principal Investigator | 2022-2025

 

Related News

Counting down to World Cancer Research Day, 24 September: lend your support to this year’s campaign entitled Cancer Research Works, Driving Progress Together

Barcelona, August 24, 2021. Launched back in 2016 by Spanish Association against Cancer (AECC), and organized in collaboration with the…

24 Aug 2021
A possible new combination of treatments to combat cancer

A new joint effort by the Hospital del Mar Research Institute, the Vall d’Hebron Institut d’Oncologia (VHIO), IDIBELL, and the…

26 Oct 2023
Dr. Joan Seoane
Recent studies show that MSC-1 LIF blockade is safe and well tolerated in patients with advanced solid tumors and point to LIF as a as a novel drug target in immune-oncology

Published in ESMO Open, results of a phase I first-in-human study co-authored by investigators at the Vall d’Hebron Institute of…

15 Dec 2022
Immune cells in cerebrospinal fluid: predictors of response to immunotherapy against brain metastasis

The analysis of immune cells infiltrating cerebrospinal fluid enables the characterization of the tumor microenvironment in brain metastases. Findings reported today in…

08 Mar 2021
Proof-of-concept study points to the placenta as a protective barrier against COVID-19 during pregnancy

Findings from a comprehensive clinical, morphological, and molecular analysis of a cohort of 37 pregnant women with and without SARS-CoV-2…

18 Feb 2021
Under the review spotlight: the promise of combined preclinical cancer modelling in immuno-oncology

In an invited Viewpoint article recently published open access and ahead of print in the journal Molecular Oncology*, VHIO’s Joan…

15 Jun 2023
Dr. Joan Seoane
Novel T cell bispecific antibody shows potent anti-tumor activity in preclinical models of epidermal growth factor receptor variant III (EGFRvIII) mutant glioblastoma

Published in Molecular Cancer Therapeutics*, a journal of the American Association for Cancer Research (AACR), results of a study co-led…

02 Aug 2022
Developed by VHIO, a novel AI-based and non-invasive diagnostic tool enables accurate brain tumor diagnosis, outperforming current classification methods

Developed by VHIO’s Radiomics Group in close collaboration with researchers of the Neuro-Radiology Unit at the Bellvitge University Hospital (HUB),…

11 Mar 2024
Privacy Preferences
When you visit our website, it may store information through your browser from specific services, usually in form of cookies. Here you can change your privacy preferences. Please note that blocking some types of cookies may impact your experience on our website and the services we offer.
Privacy Policy
You have read and agreed to our privacy policy
Required